Articles
20.11.2019
When to get scientific advice

Discussing the benefits of seeking early scientific advice and what companies need to take into cons...

Read more
Articles
13.11.2019
Medical device market access

What are the pro’s and cons of seeking NICE approval using the Medical Technologies Evaluation Pro...

Read more
Publications
06.11.2019
Pricing and market access launch excellence

Pharmaceutical companies are incorporating payer / HTA needs into their clinical and commercial laun...

Read more
Articles
11.10.2019
EUnetHTAs joint assessment facilitating HTA

How to create, facilitate, and promote sustainable Health Technology Assessment (HTA) cooperation in...

Read more
Articles
03.10.2019
Pricing and market access launch excellence

This study aims to understand the industry perspective on drivers and challenges for a successful la...

Read more
Articles
26.09.2019
New reference pricing rules for Greece 2019

Medicine prices in Greece are set by the IRP. IRP is the process of using the prices in other countr...

Read more
Articles
13.09.2019
Evidence base for Yescarta and Kymriah

Is the evidence base for high-cost CAR T-cell therapies Kymriah and Yescarta sufficient to be grante...

Read more
News
05.09.2019
Pricing and market access launch challenges

We are delighted to say that we have received fabulous feedback, with responses from 15 industry exe...

Read more
Articles
04.09.2019
Gene therapies and Managed Entry Agreements

Zolgensma launched in May 2019 in the US for $2.1 million, whilst Zynteglo was launched in the EU in...

Read more
Articles
04.09.2019
Are access agreements essential for NICE access

This study aimed to compare the use of financial agreements for oncology and non-oncology appraisals...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.